Lpez-Verdn S, Soto-Avila JJ, Zamora-Perez
AL, Lazalde-Ramos BP, Martnez-Fierro
ML, Gonzlez-Gonzlez R, Molina-Frechero N, Isiordia-Espinoza MA, Bologna-Molina R. Patients with advanced oral
squamous cell carcinoma have high levels of soluble E-cadherin in the saliva. Med Oral Patol Oral Cir Bucal. 2017 Nov 1;22
(6):e694-701.
doi:10.4317/medoral.21907
http://dx.doi.org/doi:10.4317/medoral.21907
|
1. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science.
1991;251:1451-5. |
|
|
|
|
|
2. Hanahan D and Weinberg RA. Hallmarks of Cancer: The Next Generation.
Cell. 2011;144:646-74. |
|
|
|
|
|
3. Sakaki T, Tamura I, Kadota H, Kakudo K. Changing expression of E- and
P-cadherin during rat tongue carcinogenesis
induced by
4-nitroquinoline1-oxide. J Oral Pathol Med. 2003;32:530-7. |
|
|
|
|
|
4.
Lewis JE, Jensen PJ, Johnson KR, Wheelock MJ. E-cadherin mediates adherens junction organization through protein kinase C. J Cell Sci. 1995;107:3615-21. |
|
|
|
|
|
5. Knudsen KA, Soler AP, Johnson KP, Wheelock
MJ. Interactions of alpha-actin
with the cadherin catenin cell–cell adhesion complex via a-catenin. J Cell Biol. 1995;130:67-77. |
|
|
|
|
|
6. Larue L, Antos C, Butz S, Huber O, Delmas V, Dominis M, et al. A role for cadherins in tissue formation. Development.
1996;122:3185-94. |
|
|
|
|
|
7.
Rosado P, Leuqerica-Fernndez P, Fernndez S, Allonca E, Villallan L, de
Vicente JC. E-cadherin and β-catenin expression in well-differentiated and moderately
differentiated oral squamous
cell carcinoma: relation with clinical variables. Br J
Oral Maxillofacial Surg.
2013;51:149-56. |
|
|
|
|
|
8. Lai-Kiu L, Xiao-Yun J, Xiang-Xiang Z, Dong-Miao W, Xiao-Ling S, Hong-Bing J. Upregulation
of vimentin and aberrant expression of E-cadherin/β-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213-24. |
|
|
|
|
|
9. Sridevi U, Jain A, Nagalaxmi V, Kumar UV, Goyal S. Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in
oral carcinomas. Eur J Dent.
2015;9:364-72. |
|
|
|
|
|
10. Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, et
al. Markers of Epithelial
to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). PLOS One
2014;9:e94273. |
|
|
|
|
|
11.
David JM and Rajasekaran AK. Dishonorable
Discharge: The oncogenic roles of cleaved E-cadherin fragments. Cancer Res 2012;72:1-7. |
|
|
|
|
|
12. Katayama M, Hirai S, Kamihagi K, Nakawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994;69:580-5. |
|
|
|
|
|
13. Tsaur I, Thurn K, Juengel E, Gust KM, Borgmann H, Mager R. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Res 2015;34:43. |
|
|
|
|
|
14.
Chan AOO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al.
Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001;48:808-11. |
|
|
|
|
|
15.
Wong DT. Towards a simple, saliva-based test for the detection of oral cancer 'oral fluid (saliva), which
is the mirror of the body, is a perfect
medium to be explored for health and disease surveillance'. Expert Rev Mol Diagn 2006;6:267-72. |
|
|
|
|
|
16.
AJCC: Lip and Oral cavity.
En: Edge SB, Byrd DR, Compton CC, et al., 7th eds. En: AJCC Cancer
Staging Manual. 8th ed. New York, NY: Springer, 2010, pp 29-40. |
|
|
|
|
|
17. National Cancer Institute available in
https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci
accessed August 19, 2016. |
|
|
|
|
|
18.
Barnes L, Eveson JW, Reichert
P, et al. World Health Organization classification of tumors. Lyon: IARC Press, 2005. |
|
|
|
|
|
19.
Wong DT. Salivary Diagnostics:
Amazing as it might seem, doctor can detect and monitor diseases using molecules found in a sample of spit. Am Sci. 2008;96:37-43. |
|
|
|
|
|
20. Arafah M, Kfoury HK, Zaidi SN. HER2/neu Immunostaining in invasive Breast Cancer: Analysis of False Positive Factors.
Oman Med J.
2010;25:261-3. |
|
|
|
|
|
21. Al Kassam C, Alvarez-Marcos C,
Blanco I, de Los Troyos JR, Llorente JL. Diagnostic value of E-cadherin, MMP-9, activated
MMP-13 and anti-p53 antibodies in squamous cell carcinomas of
head and neck. Med Clin (Barc). 2007;29:761-5. |
|
|
|
|
|
22. Zimmermann BG, Park NJ, Wong DT. Genomic
targets in saliva. Ann N Y Acad Sci.
2007;1098:184-91. |
|
|
|
|
|
23. Vered M, Allon I, Buchner A, Dayan D. E-cadherin in oral SCC: An analysis of the confounding literature and new insights related to its immunohistochemical
expression. Histol Histopathol. 2012;27:141-50. |
|
|
|
|
|
24.
Wang C, Liu X, Chen Z, Huang H, Jin Y, Kolokythas A, et al. Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma. Mol Carcinog.
2013;52:229-36. |
|
|
|
|
|
25. Jiang Y, Liao L, Shrestha C, Ji S, Chen Y, Peng J et al. Reduced expression of E-cadherin and
p120-catenin and elevated expression
of PLC- γ1 and PIKE are associated with aggressiveness of oral squamoous cell carcinoma. Int J Clin Exp
Pathol. 2015;8:9042-51. |
|
|
|
|
|
26. Tanaka N, Odajma T, Ogi K, Ikeda T, Satoh M. Expression of E-cadherin, α-catenin and
β-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. B J of
Cancer. 2003;89:557-63. |
|
|
|
|
|
27. Diniz-Freitas M, Garca-Caballero T, Antnez-Lpez J,
Gndara-Rey JM, Garca-Garca A. Reduced E-cadherin expression is an indicator
of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol. 2006;42:190-200. |
|
|
|
|